By Josh White
Date: Monday 03 Nov 2025
(Sharecast News) - Hutchmed unveiled new details on its expanding oncology pipeline and research strategy, including the launch of its next-generation antibody-targeted therapy conjugate (ATTC) platform, during its annual research and development update on Monday.
| Vesting of awards under Long Term Incentive Plan | 21-Oct-2025 | 09:30 | RNS |
| Appointment of Independent Non-executive Director | 14-Oct-2025 | 09:30 | RNS |
| Total Voting Rights | 30-Sep-2025 | 09:30 | RNS |
| Directorate Change | 26-Aug-2025 | 07:00 | RNS |
| 2025 Interim Results | 07-Aug-2025 | 12:00 | RNS |
| Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
| Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
| Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
| Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
| 'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
| Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
| The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
| The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
| Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 234.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 290.00p |
| 52 Week Low | 189.00p |
| Volume | 17,297 |
| Shares Issued | 872.15m |
| Market Cap | £2,040.83m |
| Beta | 1.50 |
| RiskGrade | 226 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:35 | 2,982 @ 234.00p |
| 16:35 | 2,705 @ 234.00p |
| 16:35 | 248 @ 234.00p |
| 16:35 | 14 @ 234.00p |
| 16:35 | 7 @ 234.00p |
You are here: research